Introduction to ACIP’s Combination Vaccine Work Group

Kelly Moore, MD, MPH
Chair, Combination Vaccines Work Group

Advisory Committee on Immunization Practices
June 26, 2019
Work Group Members

**ACIP Members**
- Kelly Moore (Chair)
- Veronica McNally

**Ex Officio Members**
- Ann Schwartz (FDA)
- Jillian Doss-Walker (IHS)
- Tom Weiser (IHS)

**Liaison Representatives**
- Sarah McQueen (AAPA)
- Jennifer Hamilton (AAFP)
- Patsy Stinchfield (NAPNAP)
- Sean O’Leary (AAP)
- Elizabeth Rausch-Phung (AIM)
- Phil Griffin (AIM)


CDC Contributors

- Sara Oliver (CDC Work Group Lead, *Haemophilus influenzae* SME)
- Fiona Havers (Pertussis SME)
- Anna Acosta (Diphtheria/Tetanus SME)
- Janell Routh (Polio SME)
- Sarah Schillie (Hepatitis SME)
- Tamara Pilishvili (*Streptococcus pneumoniae* SME)
- Cindy Weinbaum (Immunization Services Division)
- JoEllen Wolicki (Immunization Services Division)
- Pedro Moro (Immunization Safety Office)
- Mike Bruce (AI/AN SME)
- Rosalyn Singleton (AI/AN SME)
Pediatric hexavalent vaccine

- Joint venture between Merck and Sanofi Pasteur
  - Diphtheria, tetanus, pertussis (DTaP5)
  - Polio (IPV)
  - *Haemophilus influenzae* type b (Hib; PRP-OMP)
  - Hepatitis B (Hep B)

- Official abbreviation: DTaP-IPV-Hib-HepB

- Given in a 3-dose series (2, 4, 6 months)

- Approved and licensed by the FDA on December 21, 2018

- Manufacturer has stated vaccine not commercially available prior to 2021
Topics Under Consideration

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be preferentially recommended for the American Indian/Alaska Native (AI/AN) population.

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be included as an option in the Vaccines for Children (VFC) Program for the infant series at 2, 4, and 6 months of age.
Topics Under Consideration

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be preferentially recommended for the American Indian/Alaskan Native (AI/AN) population
  - Preferential recommendation would require ACIP vote

- Consider if the new pediatric hexavalent vaccine (DTaP-IPV-Hib-HepB) should be included as an option in the Vaccines for Children (VFC) Program for the infant series at 2, 4, and 6 months of age
  - Requires only a VFC vote
February ACIP Presentations

- Immunogenicity and Safety of Pediatric Hexavalent Vaccine
  - Andrew Lee, Merck

- Hib Epidemiology and Vaccines in American Indian/Alaska Native Population
  - Laura Hammitt, Center for American Indian Health, Johns Hopkins

- Summary, Review of Work Group Considerations
  - Sara Oliver, CDC/NCIRD
Work Group Activities

- Work Group Calls
  - Reviewed safety and immunogenicity data
  - Reviewed Hib epidemiology and Hib vaccines among AI/AN population
  - Reviewed use of combination vaccines in infant series
  - Discussed policy options

- 2019: Publication of MMWR Policy Note
Agenda

- Summary and Relevant Evidence to Recommendations Framework
  - Sara Oliver, CDC/NCIRD

- VFC votes
  - Jeanne Santoli, CDC/NCIRD
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.